Cancer survivors in high deductible health plans are more likely to report delayed care, finds a new study. The findings of the study are published in the Journal of Oncology Practice.
Summary Answer:
Proton Beam Therapy for Cancer Treatment
Proton therapy is a form of radiotherapy for cancer treatment which uses a proton beam that is targeted precisely on the tumor cells, destroying them with minimal damage to surrounding healthy tissue. Proton therapy can treat various types of cancer.
Advertisement
‘High-deductible health plan enrollment and health savings account status may affect cancer survivorship, access to care, and health care utilization.’
Tweet it Now
High-deductible health plan (HDHP) enrollment without a health savings account (HSA) is associated with worse access to care in privately insured cancer survivors and individuals without a cancer history. HSA enrollment, coupled with an HDHP, may mitigate this effect. Associations did not vary by cancer history. Emergency department (ED) visits didn't vary significantly by insurance type in cancer survivors.
What We Did:
The 2010 to 2017 National Health Interview Survey was used to identify a nationally representative sample of privately insured adults ages 18 to 64 years (cancer survivors, n = 4,321; individuals without a cancer history, n = 95,316). The sample was categorized into six groups: three groups of cancer survivors enrolled in low-deductible health plans (LDHPs), HDHPs with HSA, and HDHPs without HSA; and three groups of adults without a cancer history enrolled in LDHPs, HDHPs with HSA, and HDHPs without HSA.
![Breast Cancer Management: Advances]( "Breast Cancer Management: Advances")
The crab that invades the breast is no more a fear factor with all the advancements that medical science and customized protocols can fight breast cancer. the recent developments in the management of breast cancer.
Separate multivariable logistic regressions were conducted to assess the association between HDHP enrollment with or without HSA status and delayed/forgone care because of cost and ED visits.
What We Found:
There were no differential impacts of HDHP enrollment and HSA status on access to care and ED visits by cancer history. However, we found that, even when covered by private insurance, cancer survivors enrolled in an HDHP with or without an HSA (8.9% and 13.9%, respectively; both P < .05) were more likely to experience delayed/forgone care compared with cancer survivors enrolled in LDHPs (7.9%).
Moreover, only one-third of HDHP enrollees, regardless of cancer history, had an HSA, which was associated with less delayed/forgone care. For ED visits, cancer survivors reported similar percentages (approximately 20%) of visits regardless of HDHP enrollment and HSA status.
Bias, Confounding Factors:
Our findings that HSA enrollment appears to mitigate problems with access to care among those with HDHPs could be confounded by greater financial capability among those who are eligible for and enroll in an HSA (e.g., financial literacy, knowledge of financing options, and assets) than those who are eligible but without an HSA. We did not have information about the reasons for enrollment in an HDHP (e.g., because of lower premiums or employers' limited plan choices).
Real-Life Implications
Health plan benefits managers, payers, and policymakers should identify reasons for low HSA participation rates, provide more education about the benefits of different health plan options to help patients understand the implications of health plans and HSAs, and develop tools to forecast medical expenses and facilitate HSA enrollment.
Source: Eurekalert
The 2010 to 2017 National Health Interview Survey was used to identify a nationally representative sample of privately insured adults ages 18 to 64 years (cancer survivors, n = 4,321; individuals without a cancer history, n = 95,316). The sample was categorized into six groups: three groups of cancer survivors enrolled in low-deductible health plans (LDHPs), HDHPs with HSA, and HDHPs without HSA; and three groups of adults without a cancer history enrolled in LDHPs, HDHPs with HSA, and HDHPs without HSA.
Breast Cancer Management: Advances
The crab that invades the breast is no more a fear factor with all the advancements that medical science and customized protocols can fight breast cancer. the recent developments in the management of breast cancer.
Advertisement
Separate multivariable logistic regressions were conducted to assess the association between HDHP enrollment with or without HSA status and delayed/forgone care because of cost and ED visits.
What We Found:
There were no differential impacts of HDHP enrollment and HSA status on access to care and ED visits by cancer history. However, we found that, even when covered by private insurance, cancer survivors enrolled in an HDHP with or without an HSA (8.9% and 13.9%, respectively; both P < .05) were more likely to experience delayed/forgone care compared with cancer survivors enrolled in LDHPs (7.9%).
Moreover, only one-third of HDHP enrollees, regardless of cancer history, had an HSA, which was associated with less delayed/forgone care. For ED visits, cancer survivors reported similar percentages (approximately 20%) of visits regardless of HDHP enrollment and HSA status.
Bias, Confounding Factors:
Our findings that HSA enrollment appears to mitigate problems with access to care among those with HDHPs could be confounded by greater financial capability among those who are eligible for and enroll in an HSA (e.g., financial literacy, knowledge of financing options, and assets) than those who are eligible but without an HSA. We did not have information about the reasons for enrollment in an HDHP (e.g., because of lower premiums or employers' limited plan choices).
Real-Life Implications
Health plan benefits managers, payers, and policymakers should identify reasons for low HSA participation rates, provide more education about the benefits of different health plan options to help patients understand the implications of health plans and HSAs, and develop tools to forecast medical expenses and facilitate HSA enrollment.
Source: Eurekalert
Drugs for Prostate Cancer
Prostate cancer is the main cause of cancer death in men. One of the treatment method includes prescribing chemotherapeutic or hormonal drugs. These are prescribed depending on the type and stage of cancer.
Advertisement
 How to Cope with Cancer PainPain occurs in about 20-50% of patients with cancer. Proper therapeutic approach can help relieve and manage the condition. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
Shorter radiation course is just as good as the regular one for women choosing breast reconstruction after mastectomy, saving time and money.
HAMMR's small size permits minimally invasive implantation, monitoring cancer status, and dynamically adjusting immunotherapy, akin to a glucose monitor.
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
